When to Start and What to Use

Slides:

Advertisements

Similar presentations

Upfront Combination Therapy vs Step-Up Approach for PAH:

Advertisements

PrEP: A Case-by-Case Approach

COPD by the Guidelines.

COPD Management.

Clinical Trials in IBD.

Managing Women Living With HIV Infection

Making Decisions With Your Osteoarthritis Patients

Gout Management.

Advances in Managing Inhibitors in Patients With Hemophilia A

Maximizing Medical Management of Knee Osteoarthritis

Pseudomonas Lung Infections in Cystic Fibrosis

Dual Antiretroviral Therapy

Access to NOAC Therapy:

T2T Guidelines Promote Shared Decision-Making

Progression After Cancer Immunotherapy in Advanced NSCLC

Patient Case Discussions in T2D: What Intensification Plan Is Best?

The Latest Data on Oral Prostacyclin Therapy in PAH

HIV Management: An Update on the Latest EACS Guidelines

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Updates in Management of Atopic Dermatitis From Real Patient Cases

Is Your Patient Engaged in Care

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Beyond the Basics: What You Need to Know About Treating Insomnia

Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Chronic Idiopathic Urticaria

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Is it Time for a Paradigm Change in HIV Management?

Access to NOAC Therapy:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Evaluating Next-Generation BTK Inhibitors

Gene Therapy: Past, Present, and Future

Exploring Personalized Prophylaxis in Hemophilia A

Optimizing Outcomes and Managing Adverse Events in CLL

Perspectives on the Impact of Inflammation in OA

Updates in Neurogenic Orthostatic Hypotension

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Multidisciplinary Management of Hyperkalemia:

Patient-Centered Management in Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

A Guideline-Based Approach to HCV Care

The Changing Field of Melanoma: Ipilimumab.

Insulin in Diabetes Management: Effective Patient Selection Is Key

Challenges in LA SCCHN.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Perspective on the Multidisciplinary Management of PAH

From Adjuvant to Metastatic in Melanoma

Getting PPG Under Control

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

The Nurse View: Spotlight on EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Merging the Art and Science of Managing nOH in Clinical Practice

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Immune Checkpoint Inhibitors in Lung Cancer

Shared Decision Making in MS

Presentation transcript:

When to Start and What to Use

Program Goals

Discussion of Off-label Product Use

When to Start Antiretroviral Therapy (1998-2013)

When to Start: DHHS Guidelines, February 2013

When to Start Therapy: Balance Now Favors Earlier ART

Reasons to Delay ART Initiation

Treatment as Prevention: HPTN 052

Communicating With Patients Regarding Initiation of ART

Communicating With Patients Regarding Initiation of ART (cont)

What to Start: DHHS Recommendations

What to Start: Preferred Initial ART

What to Start: Alternative Initial ART

What to Start: Alternative Initial ART (cont)

Selecting an Initial ARV Regimen: Communicating With Patients

Concluding Remarks

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)